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Acute or chronic kidney injury results from various insults and pathological conditions, and is accompanied by activation of
compensatory repair mechanisms. Both insults and repair mechanisms are initiated by circulating factors, whose cellular eﬀects
are mediated by activation selective signal transduction pathways. Two main signal transduction pathways are activated during
these processes, the phosphatidylinositol 3 kinase (PI-3K)/mammalian target of rapamycin (mTOR) and the mitogen-activated
protein kinase (MAPK) cascades. This review will focus on the latter, and more speciﬁcally on the role of extracellular signal-
regulated kinase (ERK) cascade in kidney injury and repair.
1.Introduction
In acute kidney injury (AKI) and chronic kidney disease
(CKD), the kidney initiates activation of signaling pathways
that act as intracellular communication lines that contribute
to structural and functional manifestations. Among the wide
array of signaling networks activated in the kidney, those
containing mammalian target of rapamycin and mitogen-
activated protein kinases (MAPKs) are more commonly
studied. The role of mTOR in kidney disease has been exten-
sively reviewed recently [1, 2]. We will focus on mitogen-
activated protein kinases (MAPK), and, more precisely, on
Erk, one of the MAPK, in this paper.
There are four diﬀerent MAPK pathways in mammalian
cells: extracellular signal-regulated kinase-1 and -2 (Erk1/2),
c-Jun N-terminal kinase (JNK),p38MAPK,and extracellular
signal-regulated kinase-5 (Erk5/BMK1) [3, 4]. Erk is mainly
activated by mitogenic stimuli such as growth factors and
hormones, and JNK and p38 are mostly activated by
stress stimuli, and, are, therefore, sometimes categorized as
stress kinases. Erk5 is activated by both stress stimuli and
growth factors [4]. MAPKs are activated as part of three-
tiered kinase cascades: they are activated by simultaneous
phosphorylation on threonine and tyrosine residues by
dual-speciﬁcity MAP kinase kinases (MAPKK), which are
themselves activated by serine/threonine phosphorylation by
MAP kinase kinase kinases (MAPKKK) [3, 4]( Figure 1).
Upstream of MAPKKKs lie additional protein kinases (such
as Ste20-related protein kinases) or members of the Ras
and Rho families of small GTPases. An additional layer of
regulation has been described in proximal tubular epithelial
cells in culture, in which activation of Src by PLCγ lies
upstream ofRasandactivatesErk[5].Pathwaysdistinctfrom
the kinase cascades described above can contributeto MAPK
activities, and to cell speciﬁcity of MAPK activation. This
paper will focus only on the role of the Erk1/2 pathway in
kidney disease.
There are greater chances of restoration of renal mor-
phology and function after acute kidney injury (AKI) [6]
than in the case of chronic kidney disease (CKD); in the
latter, similar repair mechanisms may be activated although
they rarely lead to complete restoration. In response to acute
or chronic stress, renal cells mount a response designed
to limit the extent of injury which involves activation of
antiproliferative and proapoptotic genes [6]. Later, this is
followed by steps aimed at repairing the injury caused by the
stress and the initial response; this reparative stage involves
growth factors and proliferative as well as antiapoptotic2 Journal of Signal Transduction
signals [6]. In AKI, these repair mechanisms often lead
to restoration of renal morphology and function, but in
CKD sustained activation of repair mechanisms leads to
aberrant cell proliferation, cell hypertrophy, and increased




Immediately following removal of the contralateral kidney,
hyperﬁltration occurs in the remaining kidney, and is fol-
lowed by compensatory growth, which is dueto hypertrophy
of mostly tubular epithelial cells [7]. This is a physiological
response to the removal of contralateral kidney. After
unilateral nephrectomy, mitogenic growth factors as well as
TGFβ are upregulated in the remaining kidney. Mitogenic
factors trigger the diﬀerentiated epithelial cells to exit the G0
phase and enterthe cell cycle[8]. This is caused by activation
of cyclin D1 and D3-activated kinases, CDK4 and CDK6
[9]. Entry into the cell cycle initiates a synthetic program
that allows the cells to accumulate enough material to reach
a size that permits division into two daughter cells [10,
11]. However, the concomitant increase in TGFβ stimulates
the expression of cyclin-kinase inhibitors, such p27kip1 and
p57kip2 in tubular epithelial cells [12]. This, in turn, prevents
activation of cyclin E-CDK2 which is necessary to pass the
restriction point and enter S phase, when DNA is replicated
[13]. As a consequence, tubular epithelial cells are blocked
in the late G1 phase of the cell cycle when protein synthesis
and accumulation of newly synthesized materials, including
p r o t e i n s ,o c c u rl e a d i n gt oc e l lh y p e r t o p h y .
As previously described, Erk plays a crucial role in
signaling by mitogenic growth factors, it is likely that Erk
is important in the ﬁrst phase of the hypertrophic program,
when epithelial cells enter the cell cycle. Furthermore, Erk
mediates upregulation of TGFβ in tubular epithelial cells
[14]. Thus, by promoting two crucial events in this process,
entry into the cell cycle and upregulation of TGFβ that
prevents DNA replication, Erk plays a fundamental role
in the development of compensatory kidney growth after
unilateral nephrectomy.
3.AcuteKidneyInjury
3.1. Ischemia/Reperfusion. Ischemia/reperfusion (I/R) injury
induces both functional and morphological changes in the
kidney. Necrosis, predominantly of the proximal tubule, is
the hallmark of this model of renal injury. After ischemic
injury,boththeErkandphosphatidylinositol3kinase(PI3K)
signaling pathways are activated in the kidney [15, 16],
notably in the region where thick ascending limbs pre-
dominate [15], whereas stress-activated kinases, p38MAPK
and JNK are activated in tubular epithelial cells [15]. Erk
activation is due to oxidant-induced activation of a EGF
Receptor/Ras/Raf signaling cascade [16] and blockadeof Erk
reduces cell survival after I/R injury [15]. In addition, the
























of ischemia [17] or cyclosporine A or FK506 [18]p r i o rt o
an I/R insult appears to depend on decreased activation of
p38MAPK and JNK, and increased activation of Erk. Sim-
ilarly, inhibition of monoamine oxidase after an I/R insult
potentiates Erk activation and increases proliferation but
decreases necrosis oftubularcells[19]. However,aprotective
roleforErkwascalledintoquestionbyAlderliestenetal.who
showed that in vivo inhibition of Erk signiﬁcantly reduced
renal damage after I/R injury [20].
3.2. Cisplatin-Induced Nephrotoxicity. Cisplatin is one of the
most eﬀective chemotherapeutic agents used for the treat-
ment of malignant tumors, but its use is limited by its side
eﬀects, including nephrotoxicity, neurotoxicity, ototoxicity,
hair loss, nausea, and vomiting [21]. Nephrotoxicity is the
major dose-limiting factor during cisplatin treatment, as
approximately one-third of patients experience AKI within
days after cisplatin treatment [22]. Injury and death of renal
tubular cells are the key pathological occurrences in cisplatin
nephrotoxicity [23, 24], and Erk seems to play an important
role in this process.
In tubular epithelial cells in culture, cisplatin stimulation
of Erk is mediated by an EGF-R/Src cascade [25]. Activated
Erk accumulates in mitochondria following cisplatin treat-
ment and impairs its function contributing to apoptosis;
and inhibition of Erk with U0126 ameliorates mitochon-
drial dysfunction and apoptosis of tubular epithelial cells
[26]. In mice, injection of U0126 decreases Erk activation
following cisplatin administration, and oﬀers signiﬁcant
renoprotection, accompanied by decreased inﬂammation
markers, caspase 3 activity and apoptosis [27]. These data
show that Erk activation mediates the renal inﬂammation
and tubular epithelial cell apoptosis in cisplatin-induced
nephrotoxicity.
4.Chronic KidneyInjury
4.1. PolycysticKidney Disease. Autosomaldominant polycys-
tic kidney disease (ADPKD) is one of the most common
human monogenic diseases, with an incidence of 1:400 toJournal of Signal Transduction 3
1:1000 [28, 29]. It is characterized by the development and
gradualenlargementofmultipleﬂuid-ﬁlledcystswithin both
kidneys. These cysts encroach upon and destroy normal
adjacent nephrons [28]. Cyst growth and higher kidney
volumes correlate with diminishing clearance function of
the kidney in ADPKD [30]. Abnormalities of tubular cells
lining the cysts in ADPKD include increased proliferation,
increased apoptosis, abnormalities of protein sorting and
polarity, and disorganization of the underlying extracellular
matrix [31, 32]. In DBA2-pcy/pcy mice with polycystic
kidney disease, robust Erk activation is detected in the
cyst epithelium;administration of an inhibitor of the Erk
pathway, PD184352, eﬀectively reduces Erk activation and
inhibits cyst-induced gain in kidney weight, cyst index and
improves renal function [33]. This study underlines the
important role of Erk in the formation of cysts that results
from aberrant proliferation of the tubular epithelium. It also
identiﬁed Erk as a potential therapeutic target in ADPKD.
Sincetargeting mTOR with rapamycin or everolimus did not
signiﬁcantly ameliorate ADPKD in human subjects [34, 35],
the identiﬁcation of novel therapeutic targets such as Erk
could be of interest.
4.2. Chronic Mesangioproliferative Glomerulonephritis-In-
duced by Anti-Thy1 Antibody. Anti-Thy1 experimental
nephritis is a well-established model of experimental me-
sangioproliferative glomerulonephritis in the rat. Anti-Thy1
antibody binds speciﬁcally to mesangial cells and triggers
complement-induced mesangiolysis, followed by rebound
proliferation of mesangial cells [36]. In this model, maxi-
mum proliferation of mesangial cells is observed 6 days after
injection of anti-Thy1 antibody, and it is accompanied by a
signiﬁcant activation of Erk and inactivation of p38MAPK
in the glomerulus [37]. Treatment of rats with heparin
reducesglomerular cell proliferation as well as Erk activation
and restores p38MAPK activation [37]. Injection of U0126,
the MEK1 inhibitor, to rats 3 days after injection of Thy1
blocks Erk activation and returns the number of prolifer-
ating glomerular cells to normal at day 6 [38]. Together,
these studies demonstrate that Erk mediates and p38MAPK
opposes the proliferative response in mesangioproliferative
glomerulonephritis.
The role of ERK in cellular proliferation has been
extensively studied. In resting conditions, Erk is anchored
in the cytoplasm by its association with the microtubule
network [39]a n do t h e rs c a ﬀolding proteins, such as Sef [40]
and PEA15 [41]. Activation of Erk by mitogens is biphasic:
a ﬁrst, robust, and transient phase peaks at 5–10min and
is followed by a second, weaker but more sustained phase
lasting several hours [42, 43]. Nuclear translocation of Erk
occurs within minutes of stimulation, is reversible upon
removal of the mitogenic stimulus, and lasts throughout the
G1 phase of the cell cycle [44]. Nuclear Erk is inactivated
during the G1/S phase transition and is exported back to the
cytosol[44].Inthenucleus,Erkphosphorylatesandactivates
transcription factors,suchasElk1andc-Fos,which stimulate
the expression of several growth-related genes [45]. It is
important to remember that Erk activation in the nucleus is
required butnot suﬃcientforsuccessfulprogression through
the cell cycle [8].
4.3. Rat Model of Progressive Membranous Nephropathy
(Heymann Nephritis, PHN). Heymann nephritis is a model
of membranous nephropathy characterized by complement-
dependent injury to podocytes. Injection of sublytic doses
of complement (C5b-9) causes kidney damage in rats, that
is restricted to podocytes. In these cells, C5b-9 causes
DNA damage and cytoskeleton remodeling, along with Erk
activation and upregulation of p53 and p21cip1 [46]. Actin
cytoskeleton remodeling seems to cause localized activation
of Erk and selective phosphorylation of substrates, such as
c P L A 2b u tn o tE l k 1[ 47].
Inhibiting Erk in vivo in PHN worsened DNA damage
in podocytes and reduced the upregulation of p21cip1
[46], suggesting a protective role of Erk in this model.
In spite of chronic activation of Erk after overexpression
of MEK, its upstream kinase, exacerbates complement-
mediated podocytes in culture [47], suggesting a deleterious
role for Erk. A possible explanation for this discrepancy is
that overexpression of MEK causes excessive Erk activation
that far exceeds what is seen in PHN in vivo and overcomes
the protective role of Erk observed in vivo. These observa-
tions also emphasize the importance of context in assessing
the role of Erk, while it may mediate injury response in the
kidneyinonecontext,forexample,cisplatinum,itisinvolved
in renal defense in another, for example, PHN.
4.4. Unilateral Ureteral Obstruction. Unilateral ureteral ob-
struction (UUO) in rodents generates progressive renal
ﬁbrosis due to marked renal hemodynamic and metabolic
changes, followed by tubular injury and cell death by apop-
tosis or necrosis, with interstitial macrophage inﬁltration.
Proliferation of interstitial ﬁbroblasts with myoﬁbroblast
transformation leads to excess deposition of the extracellular
matrix and renal ﬁbrosis. Immediately following obstruc-
tion, a biphasic activation of Erk occurs: an early, transient
phase (30min after obstruction) of stimulation is seen in
the collecting duct; this is followed by a sustained phase (4
to 7 days) in the collecting duct, the tubular epithelial cells
and the cortical interstitium [48–50]. The latter phase of
Erk activation has been attributed to oxidative stress [49],
and its blockade prevents interstitial cell proliferation and
interstitial macrophage accumulation, but not the activation
of interstitial ﬁbroblasts and renal ﬁbrosis [50]. These results
show that Erk plays a selective and limited role after
UUO.
4.5. Diabetic Nephropathy. Characteristic morphologic
changes in diabetic nephropathy (DN) include kidney
hypertrophy, glomerular basement membrane thickening,
and the accumulation of mesangial matrix [51, 52]. Later in
the disease, progressive tubulointerstitial injury and ﬁbrosis
are observed [51, 52]. Renal enlargement, one of the ﬁrst
structural changes in DN, is due to the hypertrophy of
existing glomerular and tubular cells rather than to cellular
proliferation [51–54].4 Journal of Signal Transduction
4.5.1. Erk and Global Protein Synthesis. As described earlier,
cellular hypertrophy is the consequence of a failure to escape
the late G1 phase, when global protein synthesis takes place,
and to complete the cell cycle. Cellular accumulation of
protein during hypertrophy could be due both to increase
in its synthesis and decrease in degradation. Stimulation of
protein synthesis is due to the coordinated increase in the
transcription of their respective genes, and the translation of
theirmRNAs;thelatteristhoughttobetherate-limiting step
in gene expression [55, 56]. Regulation of mRNA translation
can occur at the levels of both increase in eﬃciency of
translation and capacity for translation. The former involves
events occurring in the initiation and elongation phases of
mRNA translation [57], whereas the latter is regulated at the
level of ribosome biogenesis and assembly.
(i) Erk in Initiation and Elongation Phases of Translation.
When a signal for increasing proteinsynthesis isreceived, the
cell ramps up the process of translating the codonsin mRNA
into respective peptide, that is, mRNA translation. Transla-
tion occurs in three phases [56, 58]. During the initiation
phase, several eukaryotic initiation factors (eIFs) assemble
intotwolargemultimericcomplexes,thatis,thepreinitiation
complex (PIC) consisting of eIF1, 1A, eIF3, eIF5, eIF2+
initiator methionyl tRNA and the 40S ribosomal subunit,
and, the eIF4F complex consisting of eIF4E, eIF4G, and
eIF4A [59]. The cap-binding protein eIF4E is held inactive
by its binding protein, 4E-BP1, in the resting state, and is
released by phosphorylation of the latter when translation
is stimulated [60]. Free eIF4E undergoes phosphorylation
on Ser209 and forms eIF4F complex with eIF4G and eIF4A
and binds to the cap of mRNA at its 5 end. Due to binding
between eIF3 and eIF4G, a bridge is now formed between
PIC and eIF4F, which brings 40S ribosomal subunit to the
proximity of the mRNA. After a complex set of reactions,
the 60Ssubunit joins 40S subunit forming the 80Sribosomal
unit and the eIFs fall away from the complex but initiator
methionyl tRNA remains. The 80S unit successfully localizes
t ot h eA U Gc o d o no nt h em R N A ,m a r k i n gt h ee n do f
initiation phase of translation.
All three of translation phases, initiation, elongation,
and termination are exquisitely regulated [56, 57]. For
instance, both initiation and elongation phases are regulated
by the PI3K-Akt-mTOR signaling pathway, which ensures
the coordinated activation of these two critically important
events and the continuous “ﬂow” of mRNA translation and
ultimately protein synthesis. Additional layers of regulation
allow ﬁne tuning of mRNA translation. One such layer is
represented by the Erk signaling pathway, which indirectly
regulates the initiation phase of mRNA translation. One
of Erk substrates, MAPK interacting kinase1 (Mnk1) phos-
phorylates eIF4E [61–63]. In contrast to mTOR-dependent
phosphorylation of 4E-BP1 which is transient, Mnk1-
dependent phosphorylation of eIF4E is persistent [64]. In
renalepithelialcellsundergoinghypertrophy underthestim-
ulationofVEGF,Ser209phosphorylationofeIF4Eappearsto
be needed for increase in protein synthesis [5]. Investigation
of signaling regulation showed that VEGF recruited VEGF
receptor type 2 to activate phospholipase Cγ,S r c ,R a f ,M E K ,
Erk pathway in stimulating Mnk1, eIF4E phosphorylation,
and protein synthesis (ibid). These data show that Erk plays
an important role in increasing the eﬃciency of translation.
(ii) Erk and Ribosome Biogenesis. Cell growth, or increase
in cell mass, requires a large increase in the number of
ribosomes. In mammals, transcription of ribosomal DNA
coding for ribosomal RNA is activated by upstream-binding
factor (UBF) and selectivity factor 1. UBF activates rRNA
gene transcription by recruiting RNA polymerase I to
the rDNA promoter, by stabilizing binding of TIF-IB/SL1,
and by displacing nonspeciﬁc DNA-binding proteins such
as histone H1 [65, 66]. UBF function is regulated by
phosphorylation by various kinases, such as Erk, casein
kinase 2 (CK2), and cyclin-dependent kinases (CDK) [67].
Phosphorylation of Thr117 and Thr201 by Erk is essential
for transcription elongation by RNA polymerase I [68,
69], whereas phosphorylation by CK2 and CDKs in the
carboxy-terminal domain aﬀect protein-protein interactions
and activates rDNA transcription indirectly [70, 71]. Recent
work from our lab has shown that high-glucose-induced
hypertrophy and protein synthesis in glomerular epithelial
cells is associated with increase in rDNA transcription (to
generate ribosomal RNA) demonstrating ribosomal biogen-
esis. This process is dependent on UBF phosphorylation
on Ser388 that was partly under the control of Erk [72].
Increase in Ser388 phosphorylation of UBF was also found
in kidney parenchyma from rodent models of type 1 and
type 2 diabetes, coinciding with kidney hypertrophy [72],
suggestingthat increased ribosomal biogenesisoccurs invivo
in hypertrophic kidney during diabetes.
Ribosome assembly is an extremely complex process
that involves four ribosomal RNAs (rRNAs) and approxi-
mately 80 ribosomal proteins [73]. In addition, more than
200 additional proteins and noncoding RNAs participate
in the production of 60S and 40S ribosomal subunits.
Ribosome assembly and activity requires posttranslational
modiﬁcations of ribosomal proteins and Erk is involved
in this process. In addition to generating ribosomal RNA,
augmented protein synthesis involves activation of a number
of proteins that are part of 40S (small, S) and 60S subunits
(large, L). Ribosomal protein 6 (rpS6) and 3 (rpS3) of the
40S subunit are commonly studied.
(iii) Ribosomal Protein S6 (rpS6). Ribosomal Protein S6acti-
vation occurs during cell growth and it is a determinant of
cell size [74]. Activation of rpS6 requires phosphorylation of
conserved serine residues that is mediated by p70S6K (S6K1)
[75]. However, the fact that in mice lacking both S6K1 and
S6K2,phosphorylation ofrpS6onSer235/236was conserved
indirectly indicated that other kinases could compensate.
Further studies have shown that this phosphorylation was
mediated by p90rsk that was itself activated by Erk [76].
Although Erk-driven rpS6 phosphorylation is functionally
relevant in T-cell receptor signaling in CD8+ T cells [77], its
signiﬁcance in renal disease has not yet been established.Journal of Signal Transduction 5
(iv) Ribosomal Protein S3 (rpS3). Ribosomal Protein S3
possesses twoindependentfunctions. Inthe cytosol,it ispart
of the 40S subunit of the ribosome and as such participates
in the initiation of mRNA translation [78]. In the nucleus,
it functions as an endonuclease and is involved in DNA
repair [79]. The subcellular localization of rpS3 is regulated
by phosphorylation by several kinases, including Erk [80].
Phosphorylation of rpS3 on Ser42 by Erk triggers its nuclear
translocation [80]. Activation of Erk can thus repress mRNA
translation and stimulate DNA repair, preventing the cells
from translating aberrant mRNAs. It is therefore possible
that sustained activation of Erk during kidney hypertrophy
in type 2 diabetes [81] could lead to a decreased availability
of rpS3 for mRNA translation, thereby limiting protein
synthesis and cell growth.
4.5.2. Erk and Selective Protein Synthesis. Accompanying
renal hypertrophy, the accumulation of extracellular matrix
proteins such as type IV collagen, laminin, ﬁbronectin, is
the other cardinal manifestation in diabetic kidney disease.
Progressive accumulation of matrix proteins accounts for
renal ﬁbrosis in diabetic kidney disease and is a major
determinant of progressive loss of kidney function [82].
The role of the Erk pathway on the stimulation of selective
synthesis of matrix proteins was investigated by our group.
We reproduced the type 2 diabetic milieu (high glucose
and high insulin) and studied its eﬀect on synthesis of
an important kidney extracellular matrix protein, laminin
β1, by proximal tubular epithelial cells in culture. High
glucose and high insulin, alone or in combination, triggered
rapid synthesis of laminin β1w i t h i n5 m i no fs t i m u l a t i o n
[83]. All three conditions activated the PI3K-Akt-mTOR
and Erk pathways in parallel and inhibition of either
pathway prevented the rapid synthesis of laminin β1. In
insulin-treated kidney epithelial cells, Erk stimulation was
downstream of PI3K, which may partly explain the common
modeofregulation oflamininsynthesis bybothkinases[84].
5.Conclusion
Erk ﬁgures prominently in mediating kidney cell responses
to a variety of diverse stimuli. This occurs in the physiologic
setting such as compensatory kidney hypertrophy and in
pathologic conditions such as models of glomerular and
tubulointerstitial diseases. It should be noted that in the set-
ting ofdiseases, it isnot wise togeneralize thatErk activation
always results in tissue injury in the kidney. As reviewed
above, inhibition of Erk could worsen speciﬁc kidney
diseases. Thus, it is important to extend our knowledge of
disease-speciﬁc regulation of Erk and then contemplate ways
to modulate its activity. This requires better understanding
of the role of Erk in all phases of individual kidney diseases
before its modulation is planned.
Acknowledgments
D. Feliers is supported by the American Heart Association
(Grant SDG 0630283N) and the Juvenile Diabetes Research
Association (Grant 1-2010-141/JDRF); B. S. Kasinath is
supported by the National Institute of Health (Grants,
DK077295 and RC2AGO36613), and the Veterans Adminis-
tration Research Service.
References
[1] W. Lieberthal and J. S. Levine, “The role of the mammalian
target of rapamycin (mTOR) in renal disease,” Journal of the
American SocietyofNephrology,vol.20,no.12,pp. 2493–2502,
2009.
[2] B. S. Kasinath, M. M. Mariappan, K. Sataranatarajan, M. J.
Lee, G. GhoshChoudhury, and D. Feliers, “Novel mechanisms
of protein synthesis in diabetic nephropathy - Role of mRNA
translation,” Reviews in Endocrine and Metabolic Disorders,
vol. 9, no. 4, pp. 255–266, 2008.
[ 3 ] T .S .L e w i s ,P .S .S h a p i r o ,a n dN .G .A h n ,“ S i g n a lt r a n s d u c t i o n
through MAP kinase cascades,” Advances in Cancer Research,
vol. 74, pp. 137–139, 1998.
[4] J. M. Kyriakis and J. Avruch, “Mammalian mitogen-activated
protein kinasesignaltransduction pathwaysactivated by stress
and inﬂammation,” Physiological Reviews,v o l .8 1 ,n o .2 ,
pp. 807–869, 2001.
[5] M. M. Mariappan, D. Senthil, K. S. Natarajan, G. G.
Choudhury, and B. S. Kasinath, “Phospholipase Cγ-Erk axis
in vascular endothelial growth factor-induced eukaryotic
initiation factor 4E phosphorylation and protein synthesis
in renal epithelial cells,” The Journal of Biological Chemistry,
vol. 280, no. 31, pp. 28402–28411, 2005.
[6] S. K. Nigam and W. Lieberthal, “Acute renal failure. III. The
role of growth factors in the process of renal regeneration and
repair,” American Journal of Physiology, vol.279, no. 1, pp. F3–
F11, 2000.
[7] I. Sinuani,I. Beberashvili, Z. Averbukh, M.Cohn, I. Gitelman,
and J. Weissgarten, “Mesangial cells initiate compensatory
tubular cell hypertrophy,” American Journal of Nephrology,
vol. 31, no. 4, pp. 326–331, 2010.
[8] S. M. Jones and A. Kazlauskas, “Growth-factor-dependent
mitogenesis requires two distinct phases of signalling,” Nature
Cell Biology, vol. 3, no. 2, pp. 165–172, 2001.
[9] S. I. Reed, “Control of the G/S transition,” Cancer Surveys,
vol. 29, pp. 7–23, 1997.
[10] W. A. Wells, “Does size matter?” J o u r n a lo fC e l lB i o l o g y ,
vol. 158, no. 7, pp. 1156–1159, 2002.
[11] B.A.EdgarandK.J.Kim,“Sizingupthecell,”Science,vol.325,
no. 5937, pp. 158–159, 2009.
[12] I. Sinuani, J. Weissgarten, I. Beberashvili et al., “The cyclin
kinase inhibitor p57 regulates TGF-β-induced compensatory
tubular hypertrophy:eﬀect of the immunomodulator AS101,”
Nephrology Dialysis Transplantation, vol. 24, no. 8, pp. 2328–
2338, 2009.
[13] R. Conradie, F. J. Bruggeman, A. Ciliberto et al., “Restriction
point control of the mammalian cell cycle via the cyclin
E/Cdk2:p27 complex,” FEBS Journal, vol. 277, no. 2, pp. 357–
367, 2010.
[14] M. Zhang, D. Fraser, and A. Phillips, “ERK, p38, and Smad
signalingpathwaysdiﬀerentiallyregulate transforminggrowth
factor-β1 autoinduction in proximal tubular epithelial cells,”
American Journal of Pathology, vol. 169, no. 4, pp. 1282–1293,
2006.
[15] J. F. di Mari, R. Davis, and R. L. Saﬁrstein, “MAPK activation
d e t e r m i n e sr e n a le p i t h e l i a lc e l ls u r v i v a ld u r i n go x i d a t i v e6 Journal of Signal Transduction
injury,” American Journal of Physiology, vol. 277, no. 2,
pp. F195–F203, 1999.
[ 1 6 ]D .S .K w o n ,C .H .K w o n ,J .H .K i m ,J .S .W o o ,a n dJ .S .J u n g ,
“Signal transduction of MEK/ERK and PI3K/Akt activation
by hypoxia/reoxygenation in renal epithelial cells,” European
J o u r n a lo fC e l lB i o l o g y , vol. 85, no. 11, pp. 1189–1199, 2006.
[ 1 7 ]K .M .P a r k ,A .C h e n ,a n dJ .V .B o n v e n t r e ,“ P r e v e n t i o no f
kidney ischemia/reperfusion-induced functional injury and
JNK, p38, and MAPK kinase activation by remote ischemic
pretreatment,” The Journal of Biological Chemistry, vol. 276,
no. 15, pp. 11870–11876, 2001.
[ 1 8 ]C .W .Y a n g ,H .J .A h n ,J .Y .J u n ge ta l . ,“ P r e c o n d i t i o n i n g
withcyclosporineAorFK506diﬀerentially regulates mitogen-
activated protein kinase expression in rat kidneys with
ischemia/reperfusion injury,” Transplantation, vol. 75, no. 1,
pp. 20–24, 2003.
[19] O. R. Kunduzova, P. Bianchi, N. Pizzinat et al., “Regulation
of JNK/ERK activation, cell apoptosis,and tissue regeneration
bymonoamineoxidasesafterrenalischemia-reperfusion,”The
FASEB Journal, vol. 16, no. 9, pp. 1129–1131, 2002.
[20] M. Alderliesten, M. de Graauw, J. Oldenampsen et al.,
“Extracellular signal-regulated kinase activation during renal
ischemia/reperfusion mediates focal adhesion dissolution and
renal injury,” American Journal of Pathology, vol. 171, no. 2,
pp. 452–462, 2007.
[21] V. Cepeda, M. A. Fuertes, J. Castilla, C. Alonso, C. Quevedo,
and J. M. P´ erez, “Biochemical mechanisms of cisplatin cyto-
toxicity,” Anti-Cancer Agents in Medicinal Chemistry,v o l .7 ,
no. 1, pp. 3–18, 2007.
[22] M. H. Hanigan and P. Devarajan, “Cisplatin nephrotoxicity:
molecular mechanisms,” Cancer Therapeutics,v o l .1 ,p p .4 7 –
61, 2003.
[23] N. Pabla and Z. Dong, “Cisplatin nephrotoxicity: mechanisms
and renoprotective strategies,” Kidney International, vol. 73,
no. 9, pp. 994–1007, 2008.
[24] I. Arany and R. L. Saﬁrstein, “Cisplatin nephrotoxicity,”
Seminars in Nephrology, vol. 23, no. 5, pp. 460–464, 2003.
[ 2 5 ]I .A r a n y ,J .K .M e g y e s i ,H .K a n e t o ,P .M .P r i c e ,a n dR .L .
Saﬁrstein, “Cisplatin-induced cell death is EGFR/src/ERK sig-
naling dependent in mouse proximal tubule cells,” American
Journal of Physiology, vol. 287, no. 3, pp. F543–F549, 2004.
[26] G. Nowak, “Protein kinase C-α and ERK1/2 mediate mito-
chondrial dysfunction, decreases in active Na+ transport, and
cisplatin-induced apoptosis in renal cells,” The Journal of
Biological Chemistry, vol. 277, no. 45, pp. 43377–43388, 2002.
[ 2 7 ]S .K .J o ,W .Y .C h o ,S .A .S u n g ,H .K .K i m ,a n dN .H .W o n ,
“MEK inhibitor, U0126, attenuates cisplatin-induced renal
injury by decreasing inﬂammation and apoptosis,” Kidney
International, vol. 67, no. 2, pp. 458–466, 2005.
[28] P. D. Wilson, “Polycystic kidney disease,” The New England
Journal of Medicine, vol. 350, no. 2, pp. 151–164, 2004.
[29] V. E. Torres and P. C. Harris, “Autosomal dominant polycystic
kidney disease: the last 3 years,” Kidney International, vol. 76,
no. 2, pp. 149–168, 2009.
[30] J. J. Grantham, V. E. Torres, A. B. Chapman et al., “Volume
progression in polycystic kidney disease,” The New England
Journal of Medicine, vol. 354, no. 20, pp. 2122–2130, 2006.
[31] G.Aguiari,V.Trimi,M.Bogoetal.,“Novel roleforpolycystin-
1inmodulatingcellproliferationthroughcalciumoscillations
in kidney cells,” Cell Proliferation, vol. 41, no. 3, pp. 554–573,
2008.
[32] C. L. Edelstein, “Mammalian target of rapamycin and caspase
inhibitors in polycystic kidney disease,” Clinical Journal of
the American Society of Nephrology, vol. 3, no. 4, pp. 1219–
1226, 2008.
[33] S. Omori, M. Hida, H. Fujita et al., “Extracellular signal-
regulated kinase inhibition slows disease progression in mice
with polycystic kidney disease,” Journal of the American Society
of Nephrology, vol. 17, no. 6, pp. 1604–1614, 2006.
[34] G. Walz, K. Budde, M. Mannaa et al., “Everolimus in patients
with autosomaldominantpolycystic kidneydisease,” The New
England Journal of Medicine,vol.363,no.9,pp.830–840,2010.
[35] A.L.Serra,D.Poster,A.D.Kistleretal.,“Sirolimusandkidney
growthinautosomaldominantpolycystickidneydisease,”The
New England Journal of Medicine, vol. 363, no. 9, pp. 820–829,
2010.
[36] W. M. Bagchus, M. F. Jeunink, and J. D. Elema, “The
mesangium in anti-Thy-1 nephritis. Inﬂux of macrophages,
mesangial cell hypercellularity, and macromolecular accumu-
lation,”American Journal of Pathology,vol.137,no.1,pp. 215–
223, 1990.
[37] D. Bokemeyer, T. Ostendorf, U. Kunter, M. Lindemann, H.
J. Kramer, and J. Floege, “Diﬀerential activation of mitogen-
activated protein kinases in experimental mesangioprolifer-
ative glomerulonephritis,” Journal of the American Society of
Nephrology, vol. 11, no. 2, pp. 232–240, 2000.
[38] D. Bokemeyer, D. Panek, H. J. Kramer et al., “In vivo
identiﬁcation of the mitogen-activated protein kinase cascade
asacentralpathogenicpathwayinexperimentalmesangiopro-
liferative glomerulonephritis,” Journal of the American Society
of Nephrology, vol. 13, no. 6, pp. 1473–1480, 2002.
[ 3 9 ]A .A .R e s z k a ,R .S e g e r ,C .D .D i l t z ,E .G .K r e b s ,a n dE .H .
Fischer, “Association of mitogen-activated protein kinasewith
the microtubule cytoskeleton,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 92,
no. 19, pp. 8881–8885, 1995.
[40] S. Torii, K. Nakayama,T. Yamamoto,and E. Nishida, “Regula-
tory mechanisms and function of ERK MAP kinases,” Journal
of Biochemistry, vol. 136, no. 5, pp. 557–561, 2004.
[41] E. Formstecher, J. W. Ramos, M. Fauquet et al., “PEA-15
Mediates Cytoplasmic Sequestration of ERK MAP Kinase,”
Developmental Cell, vol. 1, no. 2, pp. 239–250, 2001.
[42] C. Kahan, K. Seuwen, S. Meloche, and J. Pouyssegur, “Coor-
dinate, biphasic activation of p44 mitogen-activated protein
kinase and S6 kinase by growth factors in hamster ﬁbroblasts.
Evidence for thrombin-induced signals diﬀerent from phos-
phoinositide turnover and adenylylcyclase inhibition,” The
Journal of Biological Chemistry, vol. 267, no. 19, pp. 13369–
13375, 1992.
[43] S. Meloche, K. Seuwen, G. Pages, and J. Pouyssegur, “Biphasic
and synergistic activation of p44(mapk) (ERK1) by growth
factors: correlation between late phase activation and mito-
genicity,” Molecular Endocrinology, vol. 6, no. 5, pp. 845–854,
1992.
[44] S. Meloche, “Cell cycle reentry of mammalian ﬁbroblasts is
accompanied by the sustained activation of p44(mapk) and
p42(mapk) isoforms in the G1 phase and their inactivation
at the G1/S transition,”Journal of Cellular Physiology, vol. 163,
no. 3, pp. 577–588, 1995.
[45] R. J. Davis, “Transcriptional regulation by MAP kinases,”
Molecular Reproduction and Development,v o l .4 2 ,n o .4 ,
pp. 459–467, 1995.
[46] J.W. Pippin,R. Durvasula,A. Petermann, K.Hiromura,W.G.
Couser, andS.J.Shankland,“DNA damageis a novelresponse
to sublytic complement C5b-9-induced injury in podocytes,”
Journal of Clinical Investigation, vol. 111, no. 6, pp. 877–885,
2003.Journal of Signal Transduction 7
[47] A. V. Cybulsky, T. Takano, J. Papillon, K. Bijian, and J.
Guillemette, “Activation of the extracellular signal-regulated
kinaseby complementC5b-9,”American Journal ofPhysiology,
vol. 289, no. 3, pp. F593–F603, 2005.
[48] T. Masaki, R. Foti, P. A. Hill, Y. Ikezumi, R. C. Atkins, and D.
J. Nikolic-Paterson, “Activation of the ERK pathway precedes
tubular proliferation in the obstructed rat kidney,” Kidney
International, vol. 63, no. 4, pp. 1256–1264, 2003.
[ 4 9 ]B .P a t ,T .Y a n g ,C .K o n g ,D .W a t t e r s ,D .W .J o h n s o n ,a n d
G. Gobe, “Activation of ERK in renal ﬁbrosis after unilateral
ureteral obstruction: modulation by antioxidants,” Kidney
International, vol. 67, no. 3, pp. 931–943, 2005.
[50] Y. Han, T. Masaki, L. A. Hurst et al., “Extracellular signal-
regulated kinase-dependent interstitial macrophage prolifer-
ation in the obstructed mouse kidney,” Nephrology,v o l .1 3 ,
no. 5, pp. 411–418, 2008.
[51] R.O.EstacioandR.W.Schrier,“Diabetic nephropathy:patho-
genesis,diagnosis,andpreventionofprogression,”Advances in
Internal Medicine, vol. 46, pp. 359–408, 2001.
[52] M. E. Molitch, R. A. DeFronzo, M. J. Franz et al., “Nephropa-
thy in diabetes,” DiabetesCare, vol.27,supplement1, pp. S79–
S83, 2004.
[53] T. H. Hostetter, “Progression of renal disease and renal
hypertrophy,” Annual Review of Physiology, vol. 57, pp. 263–
278, 1995.
[54] T. H. Hostetter, “Hyperﬁltration and glomerulosclerosis,”
Seminars in Nephrology, vol. 23, no. 2, pp. 194–199, 2003.
[55] M. K. Holz, B. A. Ballif, S. P. Gygi, and J. Blenis, “mTOR
and S6K1 mediate assembly of the translation preinitiation
complex through dynamic protein interchange and ordered
phosphorylation events,” Cell, vol. 123, no. 4, pp. 569–580,
2005.
[56] B. S. Kasinath, D. Feliers, K. Sataranatarajan, G. G. Choud-
h u r y ,M .J .L e e ,a n dM .M .M a r i a p p a n ,“ R e g u l a t i o no fm R N A
translation in renal physiology and disease,” American Journal
of Physiology, vol. 297, no. 5, pp. F1153–F1165, 2009.
[57] B. S. Kasinath, M. M. Mariappan, K. Sataranatarajan, M. J.
Lee, and D. Feliers, “mRNA translation: unexplored territory
in renalscience,”J ou rna lo ft heA m eri ca nSoci etyo fN ep hr ol ogy ,
vol. 17, no. 12, pp. 3281–3292, 2006.
[58] N. Sonenberg and A. G. Hinnebusch, “Regulation of trans-
lation initiation in eukaryotes: mechanisms and biological
targets,” Cell, vol. 136, no. 4, pp. 731–745, 2009.
[ 5 9 ]J .R .L o r s c ha n dT .E .D e v e r ,“ M o l e c u l a rv i e wo f4 3Sc o m p l e x
formation and start site selection in eukaryotic translation
initiation,”TheJournalofBiologicalChemistry,vol.285,no.28,
pp. 21203–21207, 2010.
[60] A. Pause, G. J. Belsham, A. C. Gingras et al., “Insulin-
dependent stimulation of protein synthesis by phosphory-
lation of a regulator of 5-cap function,” Nature, vol. 371,
no. 6500, pp. 762–767, 1994.
[61] A. J. Waskiewicz, A. Flynn, C. G. Proud, and J. A.
Cooper, “Mitogen-activated protein kinases activate the ser-
ine/threonine kinases Mnk1 and Mnk2,” EMBO Journal,
vol. 16, no. 8, pp. 1909–1920, 1997.
[62] A. J. Waskiewicz, J. C. Johnson, B. Penn, M. Mahalingam, S.
R. Kimball, and J. A. Cooper, “Phosphorylation of the cap-
binding protein eukaryotic translation initiation factor 4E by
protein kinase Mnk1 in vivo,” Molecular and Cellular Biology,
vol. 19, no. 3, pp. 1871–1880, 1999.
[63] X. Wang, A. Flynn, A. J. Waskiewicz et al., “The phospho-
rylation of eukaryotic initiation factor eIF4E in response
to phorbol esters, cell stresses, and cytokines is mediated
by distinct MAP kinase pathways,” The Journal of Biological
Chemistry, vol. 273, no. 16, pp. 9373–9377, 1998.
[64] D. Feliers, S. Duraisamy, J. L. Barnes, G. Ghosh-Choudhury,
and B. S. Kasinath, “Translational regulation of vascular
endothelial growth factorexpression in renal epithelial cells by
angiotensin II,” American Journal of Physiology, vol.288,no. 3,
pp. F521–F529, 2005.
[65] A. Kuhn and I. Grummt, “Dual role of the nucleolar
transcription factor UBF: trans-activator and antirepressor,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 89, no. 16, pp. 7340–7344, 1992.
[ 6 6 ]A .K u h n ,V .S t e f a n o v s k y ,a n dI .G r u m m t ,“ T h en u c l e o l a r
transcription activator UBF relieves Ku antigen-mediated
repression of mouse ribosomal gene transcription,” Nucleic
Acids Research, vol. 21, no. 9, pp. 2057–2063, 1993.
[ 6 7 ]D .D r y g i n ,W .G .R i c e ,a n dI .G r u m m t ,“ T h eR N Ap o l y -
merase i transcription machinery: an emerging target for the
treatment of cancer,” Annual Review of Pharmacology and
Toxicology, vol. 50, pp. 131–156, 2010.
[68] V. Y. Stefanovsky, F. Langlois,D. Bazett-Jones, G. Pelletier, and
T. Moss, “ERK modulates DNA bending and enhancesome
structure by phosphorylating HMG1-boxes 1 and 2 of the
RNA polymerase I transcription factor UBF,” Biochemistry,
vol. 45, no. 11, pp. 3626–3634, 2006.
[69] V. Y. Stefanovsky, G. Pelletier, R. Hannan, T. Gagnon-Kugler,
L. I. Rothblum, and T. Moss, “An immediate response
of ribosomal transcription to growth factor stimulation in
mammals is mediated by ERK phosphorylation of UBF,”
Molecular Cell, vol. 8, no. 5, pp. 1063–1073, 2001.
[70] R. Voit and I. Grummt, “Phosphorylation of UBF at serine
388 is required for interaction with RNA polymerase I and
activation of rDNA transcription,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 98,
no. 24, pp. 13631–13636, 2001.
[71] R. Voit, M. Hoﬀm a n n ,a n dI .G r u m m t ,“ P h o s p h o r y l a t i o n
by G-speciﬁc cdk-cyclin complexes activates the nucleolar
transcription factor UBF,” EMBO Journal, vol. 18, no. 7,
pp. 1891–1899, 1999.
[72] M. M. Mariappan, K. D’Silva, M. J. Lee et al., “Ribosomal
biogenesis induction by high glucose requires activation of
upstream binding factor in kidney glomerularepithelial cells,”
American Journal of Physiology,vol.300, no.1, pp. F219–F230,
2011.
[73] H. Lempi¨ ainen and D. Shore, “Growth control and ribosome
biogenesis,” Current Opinion in Cell Biology, vol. 21, no. 6,
pp. 855–863, 2009.
[74] I. Ruvinsky, N. Sharon, T. Lerer et al., “Ribosomal protein
S6 phosphorylation is a determinant of cell size and glu-
cose homeostasis,” Genes and Development, vol. 19, no. 18,
pp. 2199–2211, 2005.
[ 7 5 ]S .F e r r a r i ,H .R .B a n d i ,J .H o f s t e e n g e ,B .M .B u s s i a n ,a n dG .
Thomas, “Mitogen-activated 70K S6 kinase. Identiﬁcation of
in vitro 40 S ribosomal S6 phosphorylation sites,” The Journal
of Biological Chemistry, vol. 266, no. 33, pp. 22770–22775,
1991.
[76] M. Pende, S. H. Um, V. Mieulet et al., “S6K1/S6K2 mice
exhibit perinatal lethalityandrapamycin-sensitive5-terminal
oligopyrimidine mRNA translation and reveal a mitogen-
activated proteinkinase-dependentS6kinasepathway,”Molec-
ular and Cellular Biology, vol. 24, no. 8, pp. 3112–3124, 2004.
[77] R. J. Salmond, J. Emery, K. Okkenhaug, and R. Zamoyska,
“MAPK, phosphatidylinositol 3-kinase, and mammalian tar-
get of rapamycin pathways converge at the level of ribosomal
protein S6 phosphorylation to control metabolic signaling8 Journal of Signal Transduction
in CD8 T cells,” Journal of Immunology, vol. 183, no. 11,
pp. 7388–7397, 2009.
[78] U. A. Bommer, G. Lutsch, J. Stahl, and H. Bielka, “Eukaryotic
initiation factors eIF-2 and eIF-3: interactions, structure and
localization in ribosomal initiation complexes,” Biochimie,
vol. 73, no. 7-8, pp. 1007–1019, 1991.
[ 7 9 ]J .K i m ,L .S .C h u b a t s u ,A .A d m o n ,J .S t a h l ,R .F e l l o u s ,a n d
S. Linn, “Implication of mammalian ribosomal protein S3
in the processing of DNA damage,” The Journal of Biological
Chemistry, vol. 270, no. 23, pp. 13620–13629, 1995.
[80] S. Yadavilli, V. Hegde, and W. A. Deutsch, “Translocation
of human ribosomal protein S3 to sites of DNA damage
is dependant on ERK-mediated phosphorylation following
genotoxic stress,” DNA Repair, vol. 6, no. 10, pp. 1453–1462,
2007.
[81] D. Feliers, S. Duraisamy, J. L. Faulkner et al., “Activation of
renal signaling pathways in db/db mice with type 2 diabetes,”
Kidney International, vol. 60, no. 2, pp. 495–504, 2001.
[82] R. M. Mason and N. A. Wahab, “Extracellular matrix
metabolism in diabetic nephropathy,” Journal of the American
Societyof Nephrology, vol. 14, no. 5, pp. 1358–1373, 2003.
[83] M. M. Mariappan, D. Feliers, S. Mummidi, G. G. Choudhury,
andB.S.Kasinath,“Highglucose,highinsulin,andtheircom-
bination rapidly induce laminin-β1 synthesis by regulation of
mRNA translation in renal epithelial cells,” Diabetes,v o l .5 6 ,
no. 2, pp. 476–485, 2007.
[84] B. K. Bhandari, D. Feliers, S. Duraisamy et al., “Insulin
regulation of protein translation repressor 4E-BP1, an eIF4E-
binding protein, in renal epithelial cells,” Kidney International,
vol. 59, no. 3, pp. 866–875, 2001.